These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 12236805)

  • 1. UK department of health guidance on prescribing for impotence following the introduction of sildenafil: potential to contain costs in the average health authority district.
    Ashton-Key M; Sadler M; Walmsley B; Holmes S; Randall S; Cummings MH
    Pharmacoeconomics; 2002; 20(12):839-46. PubMed ID: 12236805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cost to the United Kingdom National Health Service of managing erectile dysfunction: the impact of sildenafil and prescribing restrictions.
    Wilson EC; McKeen ES; Scuffham PA; Brown MC; Wylie K; Hackett G
    Pharmacoeconomics; 2002; 20(13):879-89. PubMed ID: 12381240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A systematic review assessing the economic impact of sildenafil citrate (Viagra) in the treatment of erectile dysfunction.
    Martin AL; Huelin R; Wilson D; Foster TS; Mould JF
    J Sex Med; 2013 May; 10(5):1389-400. PubMed ID: 23347555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Valuing Viagra: what is restoring potency worth?
    Kwok YS; Kim C
    Eff Clin Pract; 1999; 2(4):171-5. PubMed ID: 10539542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Demand, appropriateness and prescribing of 'lifestyle drugs': a consultation survey in general practice.
    Ashworth M; Clement S; Wright M
    Fam Pract; 2002 Jun; 19(3):236-41. PubMed ID: 11978712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. UK issues guidance on prescribing Viagra.
    Beecham L
    BMJ; 1999 Jan; 318(7179):279. PubMed ID: 9924039
    [No Abstract]   [Full Text] [Related]  

  • 7. Impotence or importance? Judicial review in an era of explicit NHS rationing.
    Syrett K
    Mod Law Rev; 2004 Mar; 67(2):289-304. PubMed ID: 16538740
    [No Abstract]   [Full Text] [Related]  

  • 8. Cost-sharing for prescriptions of sildenafil and finasteride: a case study in veteran patients.
    Yu EI; Glassman PA; Asch SM; Paige NM; Passman LJ; Shekelle PG
    Am J Manag Care; 2001 Apr; 7(4):345-53. PubMed ID: 11310190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health care cost implications of sildenafil citrate.
    Miner M
    J Sex Med; 2004 Sep; 1(2):141-9. PubMed ID: 16422968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic cost of male erectile dysfunction using a decision analytic model: for a hypothetical managed-care plan of 100,000 members.
    Tan HL
    Pharmacoeconomics; 2000 Jan; 17(1):77-107. PubMed ID: 10747767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 'No change for guidelines on GP prescribing of NHS impotence treatments' (no sex, please, we're new labour).
    Jackson G
    Int J Clin Pract; 2001 Nov; 55(9):579. PubMed ID: 11770349
    [No Abstract]   [Full Text] [Related]  

  • 12. Private prescription costs for sildenafil within the NHS: a telephone survey.
    Mostyn PA; Crowley T; Keane FE
    Int J STD AIDS; 2004 May; 15(5):314-5. PubMed ID: 15117499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A guideline of the Japanese Society for Impotence Research for prescription of sildenafil citrate to patients with erectile dysfunction].
    Shirai M
    Nihon Rinsho; 2002 Jun; 60 Suppl 6():276-9. PubMed ID: 12166157
    [No Abstract]   [Full Text] [Related]  

  • 14. Health economics and sexual dysfunction. Based on a presentation by Cyril F. Chang, PhD.
    Am J Manag Care; 1999 Jan; 5(1 Suppl):S15-8; discussion S19-22. PubMed ID: 10345972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Prescribing of sildenafil by national insurance program physicians. What basic sexual medicine qualification is required?].
    Vauth R; Berner M; Wetterauer U; Berger M
    Fortschr Med Orig; 2001 Jan; 118(4):173-9. PubMed ID: 11217683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of erectile dysfunction and characteristics of patients before and after the introduction of sildenafil in the United Kingdom: cross sectional study with comparison patients.
    Kaye JA; Jick H
    BMJ; 2003 Feb; 326(7386):424-5. PubMed ID: 12595382
    [No Abstract]   [Full Text] [Related]  

  • 17. A retrospective, study of prescribing for erectile dysfunction in a UK population during 1997-2000: demand was neither excessive nor continuing to rise.
    Sullivan F; Donnelly L; Donnan P
    Pharmacoepidemiol Drug Saf; 2004 Aug; 13(8):557-62. PubMed ID: 15317037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impotence. Putting the pill (for men) in perspective.
    Harv Health Lett; 1998 Jun; 23(8):4-5. PubMed ID: 9644493
    [No Abstract]   [Full Text] [Related]  

  • 19. Cost effectiveness of sildenafil calls for political discussion.
    Stolk E; Busschbach J
    BMJ; 2000 Aug 19-26; 321(7259):510. PubMed ID: 11012253
    [No Abstract]   [Full Text] [Related]  

  • 20. Evaluation and therapeutic regulation of erectile dysfunction with visual stimulation test. An objective approach by using sildenafil citrate test.
    Erbağci A; Yagci F; Sarica K; Ozbek E; Topcu O
    Urol Int; 2002; 69(1):21-6. PubMed ID: 12119434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.